ClinicalTrials.gg
CompletedNCT00345761Updated Aug 16, 2010

Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer

A Phase 1/2 interventional study of Bevacizumab and Oxaliplatin in Colorectal Cancer, sponsored by Chugai Pharmaceutical. Completed at 4 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-08-16.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
78th of 183
64 · median 50
Started
2006
with 17 others
Phase 1/2
16 of 206
none open now
Registered
76th of 206
by date

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 78th largest by enrollment of the 183 interventional ones that give a count, is one of 18 that started in 2006, is one of 16 in phase 1/2, and was the 76th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000 mg/m2/day by mouth [po], day 1 pm-day 15 am every 3 weeks [q3w]), oxaliplatin (130 mg/m2 intravenously [iv], day 1 q3w) and bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.

Read the detailed description

This study will evaluate the efficacy, safety and pharmacokinetics of Capecitabine (2000 mg/m2/day po, day 1 pm-day 15 am q3w), Oxaliplatin (130 mg/m2 iv, day 1 q3w) and Bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Advanced and/or metastatic colorectal cancer
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 20-74 years of age
  • confirmed colorectal cancer
  • and/or locally advanced colorectal cancer not previously treated with chemotherapy for metastatic disease
  • At least one according to

Exclusion criteria

Exclusion Criteria:

  • Evidence of clinically detectable ascites at study treatment start
  • Major surgical procedure, open , or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study; fine needle aspiration within 7 days prior to study treatment start.
  • Evidence of bleeding diathesis or coagulopathy
  • Serious, non-healing wound, ulcer, or bone fracture
  • Chronic, daily aspirin (> 325 mg/day), anticoagulants, or other medications known to predispose to gastrointestinal ulceration
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Step 1

    Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    Step 2

    Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    Step 3

    Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • 7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)

  • 130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)

  • 2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)

06

What researchers measure

Primary outcomes

  1. Response rate: Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: event driven

  2. Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)

    Time frame: throughout study

Secondary outcomes

  1. time to progression

    Time frame: event driven

  2. overall survival

    Time frame: event driven

  3. time to response

    Time frame: event driven

  4. duration of response

    Time frame: event driven

  5. concentrations of R340 and its metabolites

    Time frame: throughout study

  6. concentrations of platinum

    Time frame: throughout study

  7. concentrations of bevacizumab

    Time frame: throughout study

  8. concentrations of vascular endothelial growth factor (VEGF)

    Time frame: throughout study

  9. concentrations of anti-bevacizumab antibody

    Time frame: throughout study

07

Study locations

4 sites
  • Hokkaido Region
    Hokkaido, Japan
  • Kanto Region
    Kanto, Japan
  • Kinki Region
    Kinki, Japan
  • Tokai Region
    Tokai, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Oct 2008 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2006
First posted
Jun 28, 2006
Start
Feb 2006
Primary completionActual
Oct 2008
CompletionActual
Jul 2010
Last update
Aug 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00345761
Collaborators
Yakult Honsha Co., LTD
First posted
Jun 28, 2006
Start date
Feb 2006
Primary completion
Oct 2008
Completion
Jul 2010
Last update
Aug 16, 2010

Study contacts

Yuji Hayashi
study chair · Clinical Development Department 3, Group 6

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Capecitabine

Start the discussion